Published in Curr Opin Lipidol on June 01, 2004
Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet (2008) 7.33
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Genetic determinants of plasma triglycerides. J Lipid Res (2010) 1.63
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) (2010) 1.43
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med (2006) 1.40
Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J Biol Chem (2008) 1.26
Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J Biol Chem (2009) 1.13
Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J (2005) 1.10
Mixed modeling and multiple imputation for unobservable genotype clusters. Stat Med (2008) 1.10
Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One (2012) 1.10
Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab (2011) 1.09
Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol (2005) 1.02
An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. J Lipid Res (2008) 1.02
Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster. Hum Hered (2006) 1.01
Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol (2008) 0.95
Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid. Cell Metab (2010) 0.94
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 0.92
Metabolomics as an extension of proteomic analysis: study of acute kidney injury. Semin Nephrol (2007) 0.92
Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm. Proteomics Clin Appl (2012) 0.91
APOE, CETP and LPL genes show strong association with lipid levels in Greek children. Nutr Metab Cardiovasc Dis (2009) 0.89
Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome. Diabetes Care (2008) 0.87
The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides. BMC Med Genet (2008) 0.86
Influences of APOA5 variants on plasma triglyceride levels in Uyghur population. PLoS One (2014) 0.86
Islet inflammation in plain sight. Diabetes Obes Metab (2013) 0.83
Candidate gene resequencing to identify rare, pedigree-specific variants influencing healthy aging phenotypes in the long life family study. BMC Geriatr (2016) 0.82
Genetics of lipid traits and relationship to coronary artery disease. Curr Cardiol Rep (2013) 0.82
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent. Pharmgenomics Pers Med (2009) 0.81
Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men. Atherosclerosis (2008) 0.80
The apolipoprotein CIII enhancer regulates both extensive histone modification and intergenic transcription of human apolipoprotein AI/CIII/AIV genes but not apolipoprotein AV. J Biol Chem (2008) 0.78
Dietary oxidized linoleic acid lowers triglycerides via APOA5/APOClll dependent mechanisms. Atherosclerosis (2008) 0.78
Association of APOA5 T1131C polymorphism and risk of coronary artery disease. Int J Clin Exp Med (2015) 0.76
Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. BMC Endocr Disord (2014) 0.76
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency. J Lipid Res (2008) 0.76
Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men. Biomed Res Int (2015) 0.75
The Association between Pediatric NAFLD and Common Genetic Variants. Children (Basel) (2017) 0.75
The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab (2010) 3.11
Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A (2011) 2.92
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med (2006) 2.86
Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci U S A (2005) 2.71
Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation (2002) 2.62
Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem (2002) 2.61
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol (2008) 1.97
Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. Endocrinology (2009) 1.90
Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle. Cell Metab (2010) 1.87
ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem (2004) 1.81
PPARalpha governs glycerol metabolism. J Clin Invest (2004) 1.79
Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arterioscler Thromb Vasc Biol (2005) 1.75
Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol (2008) 1.63
Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake. Arterioscler Thromb Vasc Biol (2007) 1.56
CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res (2003) 1.54
Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology (2006) 1.51
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. J Hypertens (2012) 1.50
MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res (2009) 1.49
Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. Endocrinology (2003) 1.47
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res (2004) 1.46
Selective parasympathetic innervation of subcutaneous and intra-abdominal fat--functional implications. J Clin Invest (2002) 1.46
Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res (2005) 1.45
Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice. Atherosclerosis (2011) 1.42
Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes (2006) 1.39
Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res (2005) 1.39
Phenotype characterisation using integrated gene transcript, protein and metabolite profiling. Appl Bioinformatics (2004) 1.38
CD36 deficiency in mice impairs lipoprotein lipase-mediated triglyceride clearance. J Lipid Res (2005) 1.35
Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol (2006) 1.34
Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. Biochim Biophys Acta (2009) 1.32
Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation (2003) 1.27
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res (2007) 1.27
ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med (2006) 1.27
Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice. J Lipid Res (2004) 1.20
Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes (2004) 1.20
Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. Diabetes (2008) 1.19
Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes (2003) 1.19
Detrimental effects of constant light exposure and high-fat diet on circadian energy metabolism and insulin sensitivity. FASEB J (2013) 1.17
The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun (2005) 1.16
Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J (2005) 1.16
Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab (2005) 1.16
Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am J Physiol Gastrointest Liver Physiol (2005) 1.15
Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS (2004) 1.13
NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis (2011) 1.12
Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis (2006) 1.11
Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes (2005) 1.11
Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation (2007) 1.09
Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. OMICS (2004) 1.08
Intestinal lipid absorption is not affected in CD36 deficient mice. Mol Cell Biochem (2002) 1.07
Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes (2006) 1.07
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation (2008) 1.06
Scavenger receptor BI plays a role in facilitating chylomicron metabolism. J Biol Chem (2004) 1.06
AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36. Biochem Biophys Res Commun (2007) 1.06
Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis (2006) 1.05
Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J (2006) 1.03
Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3 Leiden and low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol (2010) 1.03
The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J Lipid Res (2004) 1.03
Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis (2013) 1.03
Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis (2007) 1.02
Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev (2011) 1.02
Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials (2005) 1.01
Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J (2008) 1.01